Celyad SA (CYAD): Price and Financial Metrics


Celyad SA (CYAD): $1.29

-0.28 (-17.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYAD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYAD Stock Price Chart Interactive Chart >

Price chart for CYAD

CYAD Price/Volume Stats

Current price $1.29 52-week high $3.63
Prev. close $1.57 52-week low $0.46
Day low $1.26 Volume 150,700
Day high $1.43 Avg. volume 5,026,494
50-day MA $1.04 Dividend yield N/A
200-day MA $1.59 Market Cap 29.15M

Celyad SA (CYAD) Company Bio


Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.


CYAD Latest News Stream


Event/Time News Detail
Loading, please wait...

CYAD Latest Social Stream


Loading social stream, please wait...

View Full CYAD Social Stream

Latest CYAD News From Around the Web

Below are the latest news stories about CELYAD ONCOLOGY SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!

William White on InvestorPlace | January 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today!

William White on InvestorPlace | January 17, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday!

William White on InvestorPlace | December 22, 2022

Celyad Oncology Completely Shifts To Preclinical Stage, Pulls Plug On Only Human Trial Asset

Celyad Oncology (NASDAQ: CYAD) provides an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months. The company has compiled a foundational and broad IP estate. In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in areas including: Multiplexing approach of the short hairpin RNA (shRNA) platform. Dual CAR development of a next-generation NKG2D-based CAR. Development of B7-H6-targeting immunotherapies for sev

Yahoo | December 21, 2022

Read More 'CYAD' Stories Here

CYAD Price Returns

1-mo 153.94%
3-mo 18.35%
6-mo -47.35%
1-year -61.61%
3-year -88.80%
5-year -97.29%
YTD 161.72%
2022 -86.53%
2021 -53.08%
2020 -25.14%
2019 -42.62%
2018 -57.87%

Continue Researching CYAD

Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:

Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6576 seconds.